GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Skye Bioscience Inc (NAS:SKYE) » Definitions » Net Change in Cash

SKYE (Skye Bioscience) Net Change in Cash : $62.28 Mil (TTM As of Sep. 2024)


View and export this data going back to 2014. Start your Free Trial

What is Skye Bioscience Net Change in Cash?

Net Change in Cash is calculated as the total of Cash Flow from Operations , Cash Flow from Investing, Cash Flow from Financing, and Effect of Exchange Rate Changes.

Skye Bioscience's Net Change in Cash for the three months ended in Sep. 2024 was $-6.71 Mil. Its Net Change in Cash for the trailing twelve months (TTM) ended in Sep. 2024 was $62.28 Mil.

Skye Bioscience Net Change in Cash Historical Data

The historical data trend for Skye Bioscience's Net Change in Cash can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Skye Bioscience Net Change in Cash Chart

Skye Bioscience Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Net Change in Cash
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.02 0.64 6.51 -7.74 9.09

Skye Bioscience Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Net Change in Cash Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 13.65 -3.88 82.09 -9.22 -6.71

Skye Bioscience Net Change in Cash Calculation

Skye Bioscience's Net Change in Cash for the fiscal year that ended in Dec. 2023 is calculated as

Net Change in Cash= Cash Flow from Operations+Cash Flow from Investing+Cash Flow from Financing+Effect of Exchange Rate Changes
=-13.952+6.596+16.443+0
=9.09

Skye Bioscience's Net Change in Cash for the quarter that ended in Sep. 2024

Net Change in Cash=Cash Flow from Operations+Cash Flow from Investing+Cash Flow from Financing+Effect of Exchange Rate Changes
=-5.263+-1.446+0+0
=-6.71

Net Change in Cash for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $62.28 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Skye Bioscience Net Change in Cash Related Terms

Thank you for viewing the detailed overview of Skye Bioscience's Net Change in Cash provided by GuruFocus.com. Please click on the following links to see related term pages.

Skye Bioscience Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Skye Bioscience Inc (NAS:SKYE) » Definitions » Net Change in Cash
Comparable Companies
ELEV UNCY VINC ACER HEPA NLSP HARP NBIO ICU AIM OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
N/A
Address
11250 El Camino Real, Suite 100, San Diego, CA, USA, 92130
Website
https://www.skyebioscience.com
Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.
Executives
Paul A. Grayson director 10578 SCIENCE CENTER DRIVE, SUITE 200, SAN DIEGO CA 92121
Kaitlyn Melanie Arsenault officer: Chief Financial Officer 11250 EL CAMINO REAL, SUITE 100, C/O SKYE BIOSCIENCE, INC., SAN DIEGO CA 92130
Punit Dhillon director 5820 NANCY RIDGE DRIVE, SAN DIEGO CA 92121
5am Partners Vii, Llc 10 percent owner 501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107
Andrew J. Schwab director, 10 percent owner C/O 5AM VENTURES, 501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107
John D Diekman 10 percent owner C/O 5 AM VENTURES, 501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107
5am Ventures Vii, L.p. 10 percent owner 501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107
Kush Parmar 10 percent owner C/O 5AM VENTURES, 501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107
5am Partners Ii, Llc 10 percent owner 501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107
5am Co-investors Ii Lp 10 percent owner 501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107
Versant Venture Capital Iii, L.p. 10 percent owner ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
Versant Side Fund Iii, L.p. 10 percent owner ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
Versant Ventures Iii, Llc 10 percent owner ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
Scott M Rocklage 10 percent owner C/O 5AM VENTURES, 501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107
5am Ventures Ii Lp 10 percent owner 501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107

Skye Bioscience Headlines

From GuruFocus

Skye Bioscience Demonstrates Prominent Role of Peripheral CB1 Inhibition and Achieves Significant Weight Loss with Novel CB1-inhibiting Antibody, Nimacimab, in Preclinical Model

By Marketwired • 11-04-2024

SKYE Investors Have Opportunity to Join Skye Bioscience, Inc. Fraud Investigation with the Schall Law Firm

By Business Wire • 08-04-2024

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Skye Bioscience, Inc. - SKYE

By PRNewswire • 07-25-2024

Skye Bioscience Reports Third Quarter 2024 Financial Results and Recent Highlights

By Marketwired • 11-07-2024

Skye Bioscience, Inc. (SKYE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings

By Business Wire • 08-16-2024

Skye Bioscience, Inc. (SKYE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings

By Business Wire • 08-08-2024

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Skye Bioscience, Inc. - SKYE

By Marketwired • 07-20-2024

Beacon Biosignals Announces Strategic Collaboration with Skye Bioscience to Integrate Sleep Quality and Sleep Apnea Endpoints in CBEYOND��Phase 2 Trial of Nimacimab for Obesity

By Marketwired • 07-24-2024

Skye Bioscience, Inc. (SKYE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings

By Marketwired • 08-13-2024

Skye Bioscience Hosts Virtual KOL Event, �Metabolic Rewiring with CB1 Inhibition,� and Details Phase 2 Nimacimab Clinical Trial Design Including Obstructive Sleep Apnea Exploratory Endpoints

By Marketwired • 07-24-2024